Snap Analysis: Gene sequencers edge away from Illumina's woes
Friday, October 7, 2011 - 13:00
in Mathematics & Economics
(Reuters) - As Illumina Inc announced it was battling slower purchases by customers who depend on federal funding for research, several peers in gene sequencing rushed to reassure investors they don't have the same kind of risk exposure.